A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 415 participants.
Also called NCT02332824
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 415 participants
- Sponsor
- Registry
-
NCT02332824 -
U1111-1161-6858
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02332824. Randomized; quadruple masking; primary purpose treatment. Start 2014-10-16 (actual); primary completion 2016-08-18 (actual). Results posted on 2018-08-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
- Condition
- Type 2 Diabetes Mellitus and Microalbuminuria
- Intervention (Drug)
- TAK-272
- Intervention (Drug)
- TAK-272 Placebo
- Intervention (Drug)
- Candesartan cilexetil
- Intervention (Drug)
- Candesartan cilexetil Placebo
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct02332824- Content hash
80df705901ae9e1fd9b30999b63ca25956c03d657972765079f2a86ccf90383e